Presumably, connecting antipsoriatic treatment additionally with other lowering PCSK9 medications could be useful, especially when acitretin is used as a systemic drug in obese psoriatic patients with metabolic syndrome. This evidence concerns the gene PCSK9 and metabolic syndrome.